Haemonetics (HAE) closed at $122.36 on November 10, 2026, up 3.5% from the previous close, on volume of 711,608 shares (30-day average 725,340).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call Butterfly (Skip Strike) | 20-Nov-26115 : 130[2x] : 140 C | 2,344 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Globe Newswire (Tue, 10-Nov 4:10 PM ET)
TipRanks (Tue, 10-Nov 7:11 AM ET)
Bank of America Securities Reaffirms Their Buy Rating on Haemonetics (HAE)
TipRanks (Sat, 7-Nov 12:36 AM ET)
Citi Reaffirms Their Buy Rating on Haemonetics (HAE)
TipRanks (Fri, 6-Nov 9:23 AM ET)
Haemonetics’ Strong Execution and CSL Plasma Upside Support Higher $142 Price Target
TipRanks (Fri, 6-Nov 9:10 AM ET)
PRNewswire (Thu, 5-Nov 6:00 AM ET)
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
PRNewswire (Mon, 19-Oct 4:15 PM ET)
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
PRNewswire (Wed, 30-Sep 4:05 PM ET)
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Globe Newswire (Tue, 15-Sep 8:30 AM ET)
AZENTA ANNOUNCES LEADERSHIP TRANSITION
PRNewswire (Mon, 24-Aug 8:00 AM ET)
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Haemonetics trades on the NYSE stock market under the symbol HAE.
As of November 10, 2026, HAE stock price climbed to $122.36 with 711,608 million shares trading.
HAE has a beta of 0.12, meaning it tends to be less sensitive to market movements. HAE has a correlation of 0.00 to the broad based SPY ETF.
HAE has a market cap of $5.57 billion. This is considered a Mid Cap stock.
Last quarter Haemonetics reported $358 million in Revenue and $1.35 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.06.
In the last 3 years, HAE traded as high as $132.00 and as low as $47.32.
The top ETF exchange traded funds that HAE belongs to (by Net Assets): IJH, VTI, IWM, VB, VXF.
HAE has outperformed the market in the last year with a price return of +73.6% while the SPY ETF gained +11.2%. HAE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +41.3% and +2.0%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
HAE support price is $115.93 and resistance is $120.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HAE shares will trade within this expected range on the day.